Upper extremity 3‐dimensional reachable workspace analysis in dystrophinopathy using Kinect

Introduction: An innovative upper extremity 3‐dimensional (3D) reachable workspace outcome measure acquired using the Kinect sensor is applied toward Duchenne/Becker muscular dystrophy (DMD/BMD). The validity, sensitivity, and clinical meaningfulness of this novel outcome measure are examined. Methods: Upper extremity function assessment (Brooke scale and NeuroQOL questionnaire) and Kinect‐based reachable workspace analyses were conducted in 43 individuals with dystrophinopathy (30 DMD and 13 BMD, aged 7–60 years) and 46 controls (aged 6–68 years). Results: The reachable workspace measure reliably captured a wide range of upper extremity impairments encountered in both pediatric and adult, as well as ambulatory and non‐ambulatory individuals with dystrophinopathy. Reduced reachable workspaces were noted for the dystrophinopathy cohort compared with controls, and they correlated with Brooke grades. In addition, progressive reduction in reachable workspace correlated directly with worsening ability to perform activities of daily living, as self‐reported on the NeuroQOL. Conclusion: This study demonstrates the utility and potential of the novel sensor‐acquired reachable workspace outcome measure in dystrophinopathy. Muscle Nerve 52:344–355, 2015

[1]  Ruzena Bajcsy,et al.  Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by kinect , 2015, Muscle & nerve.

[2]  N Klopcar,et al.  A kinematic model of the shoulder complex to evaluate the arm-reachable workspace. , 2007, Journal of biomechanics.

[3]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[4]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[5]  Clark C. Presson,et al.  Normative and Validation Studies of the Nine-Hole Peg Test with Children , 2000, Perceptual and motor skills.

[6]  James G Wright,et al.  Measuring disability of the upper extremity: a rationale supporting the use of a regional outcome measure. , 1999, Journal of hand therapy : official journal of the American Society of Hand Therapists.

[7]  E. Hoffman.  Genotype/phenotype correlations in Duchenne/Becker dystrophy. , 1993, Molecular and cell biology of human diseases series.

[8]  G. Comi,et al.  Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes , 2014, PloS one.

[9]  C. Bombardier,et al.  Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder, and head) , 1996 .

[10]  J. Drugan,et al.  The muscular dystrophy coordinating committee action plan for the muscular dystrophies , 2016, Muscle and Nerve.

[11]  W. Stuberg,et al.  Reliability of quantitative muscle testing in healthy children and in children with Duchenne muscular dystrophy using a hand-held dynamometer. , 1988, Physical therapy.

[12]  J. Mendell,et al.  Challenges in drug development for muscle disease: A stakeholders' meeting , 2007, Muscle & nerve.

[13]  S. Pandya,et al.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. , 2009, MMWR. Morbidity and mortality weekly report.

[14]  Francesco Muntoni,et al.  Muscular dystrophy: new challenges and review of the current clinical trials , 2013, Current opinion in pediatrics.

[15]  E. Mazzone,et al.  A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy , 2012, Developmental medicine and child neurology.

[16]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[17]  J. Mendell,et al.  Emerging drugs for Duchenne muscular dystrophy , 2012, Expert opinion on emerging drugs.

[18]  D. Bentley,et al.  Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study. , 1992, JAMA.

[19]  Deborah M. Miller,et al.  The neurology quality-of-life measurement initiative. , 2011, Archives of physical medicine and rehabilitation.

[20]  B Kummer,et al.  [Anatomy and biomechanics of the shoulder]. , 1975, Hefte zur Unfallheilkunde.

[21]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[22]  Cindy Hamil,et al.  Evidence‐based path to newborn screening for duchenne muscular dystrophy , 2012, Annals of neurology.

[23]  V. Dubowitz.  The Duchenne Dystrophy Story: From Phenotype to Gene and Potential Treatment , 1989, Journal of child neurology.

[24]  R. H. Jebsen,et al.  An objective and standardized test of hand function. , 1969, Archives of physical medicine and rehabilitation.

[25]  Elizabeth Vroom,et al.  Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy , 2013, Developmental medicine and child neurology.

[26]  Marika Pane,et al.  North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy , 2010, Neuromuscular Disorders.

[27]  E. Mattsson,et al.  Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. , 2001, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[28]  K. Bushby,et al.  Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. , 2011, Clinical investigation.

[29]  Gene therapy prospects for Duchenne muscular dystrophy. , 1994, European neurology.

[30]  Caskey Ct,et al.  Gene therapy prospects for Duchenne muscular dystrophy. , 1994 .

[31]  K. Bushby,et al.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy , 1993, Journal of Neurology.

[32]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER CLINICAL ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: RELIABILITY, CONCURRENT VALIDITY, AND MINIMAL CLINICALLY IMPORTANT DIFFERENCES FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[33]  G. Comi,et al.  6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes , 2014, PloS one.

[34]  C O Bechtol,et al.  Biomechanics of the shoulder. , 1980, Clinical orthopaedics and related research.

[35]  K. Bushby,et al.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy , 1993, Journal of Neurology.

[36]  M. Brooke,et al.  Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.

[37]  A. Emery.  Duchenne muscular dystrophy or Meryon's disease , 2001, The Lancet.

[38]  Lise Worthen-Chaudhari,et al.  Proof of Concept of the Ability of the Kinect to Quantify Upper Extremity Function in Dystrophinopathy , 2013, PLoS currents.

[39]  Ruzena Bajcsy,et al.  Development and Application of Stereo Camera-Based Upper Extremity Workspace Evaluation in Patients with Neuromuscular Diseases , 2012, PloS one.

[40]  Francesco Muntoni,et al.  Dystrophin and mutations: one gene, several proteins, multiple phenotypes , 2003, The Lancet Neurology.

[41]  T. Frieden,et al.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. , 2009, MMWR. Morbidity and mortality weekly report.

[42]  Jacques Fermanian,et al.  A motor function measure scale for neuromuscular diseases. Construction and validation study , 2005, Neuromuscular Disorders.

[43]  H. Ranu,et al.  Therapeutic Exercise: Foundations and Techniques. 2nd Edn , 1992 .

[44]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[45]  C. Bombardier,et al.  Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG) , 1996, American journal of industrial medicine.

[46]  Ruzena Bajcsy,et al.  Validity, Reliability, and Sensitivity of a 3D Vision Sensor-based Upper Extremity Reachable Workspace Evaluation in Neuromuscular Diseases , 2013, PLoS currents.

[47]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[48]  L. Kunkel,et al.  Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy , 1986, Nature.

[49]  Ruzena Bajcsy,et al.  Tele-MFAsT: Kinect-Based Tele-Medicine Tool for Remote Motion and Function Assessment , 2014, MMVR.

[50]  N. Leidy,et al.  Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[51]  S A Hess,et al.  Functional stability of the glenohumeral joint. , 2000, Manual therapy.

[52]  Catherine Klersy,et al.  Quality of Life in Duchenne Muscular Dystrophy: The Subjective Impact on Children and Parents , 2011, Journal of child neurology.

[53]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[54]  Nives Klop.  Kinematic Model for Determination of Human Arm Reachable Workspace , 2005 .

[55]  Ruzena Bajcsy,et al.  Evaluation of upper extremity reachable workspace using Kinect camera. , 2013, Technology and health care : official journal of the European Society for Engineering and Medicine.

[56]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[57]  T. Voit,et al.  Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients , 2013, Neuromuscular Disorders.

[58]  C. Nowinski,et al.  Neuro-QOL and the NIH Toolbox: implications for epilepsy. , 2010, Therapy.

[59]  Jay J. Han,et al.  The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.

[60]  Jacques Fermanian,et al.  A motor function measure for neuromuscular diseases. Construction and validation study. , 2005, Neuromuscular disorders : NMD.